Interviews

MSK experts discuss FLAURA2 updates, emerging targets in mesothelioma, and next-gen immunotherapies from the 2026 European Lung Cancer Congress.

HER2-targeted ADCs show ~50% response rates in pretreated endometrial cancer, with durable responses and manageable safety profiles per 2026 SGO data.

Pancreatic cancer research tackles treatment resistance with targeted drug delivery, immune-boosting combinations, and smarter therapy pairings to extend responses in trials.

Community oncology practices can deliver chimeric antigen receptor (CAR) T-cell therapy safely, effectively, and in a sustained manner.

Lilit Karapetyan, MD, MS, discusses how a single-center trial suggests patients with poorer performance status could be eligible for tumor-infiltrating lymphocyte therapy.

Nodal burden predicts higher preoperative ctHPVDNA levels, while aggressive pathologic features paradoxically correlate with lower values in oropharynx cancer.

Roisin E. O'Cearbhaill reviews a phase 1/2 trial evaluating REGN5668, a MUC16×CD28 bispecific antibody, in combination with other targeted therapies for recurrent ovarian and endometrial cancers.

Researchers work to identify blood-based immune markers, including activated T cells and antibody levels, that may predict long-term survival in patients with glioblastoma.

Dr Naomi Haas discusses the feasibility of neoadjuvant therapy in RCC, highlighting the PROSPER trial's results and its role in treating unresectable disease.

Dr Danny Nguyen discusses the shift of clinical trials to community settings, the impact of AI in oncology, and the latest drug approvals in lung cancer care.

Relacorilant targets glucocorticoid receptor signaling to restore chemo sensitivity in platinum-resistant ovarian cancer, no biomarker testing needed.

Experts from Memorial Sloan Kettering Cancer Center discuss updates from the 2026 European Lung Cancer Congress.

Dr Komrokji explains how the IPSS-M improves prognostic precision in MDS but cautions that upstaging alone should not automatically drive treatment escalation.

Lilit Karapetyan, MD, MS, discusses a single-center trial of reduced-intensity conditioning before tumor-infiltrating lymphocyte therapy in melanoma.

Dr Charles Simone highlights the necessity of multidisciplinary care and advanced radiation, like proton therapy, to improve survival in rare thymic cancers.

Dr. Pavlos Msaouel notes that platinum-based chemotherapy remains a stalwart treatment but immunotherapies lead to less-than-optimal results.

Learn the warning signs of renal medullary carcinoma—sickle cell trait, right-sided mass—and why INI1 testing changes therapy and survival.

New CLL strategies tackle drug resistance with BTK degraders, bispecific antibodies and CAR T combos, offering hope for heavily pretreated patients.

Immunohistochemistry is the gold standard for diagnosing renal medullary carcinoma, as genetic sequencing often misses key SMARCB1 alterations.

Dr Mehra discussed HPV-positive oropharyngeal cancer, focusing on balancing high cure rates while minimizing toxicity through careful patient selection.

Findings from the PARADIGM trial suggest that the use of azacitidine and venetoclax could replace intensive chemotherapy in younger, fit patients with acute myeloid leukemia.

Dr Dale Shepard of Cleveland Clinic discusses the PYNNACLE trial results for rezatapopt, the first successful small-molecule reactivation of mutant p53.

Dr Nicolas Girard discusses PALOMA-2 at ELCC 2026, highlighting the 85% ORR and safety of subcutaneous amivantamab plus lazertinib in first-line EGFR+ NSCLC.

As one of the rare subtypes of renal cell carcinoma, renal medullary carcinoma presents with some distinct signs: male, Black, between 12 and 45 years of age, sickle cell trait, and a mass in the right kidney.

The phase 3 ATOMIC trial is changing the way we treat stage III dMMR colon cancer. In this video, Dr. Sinicrope breaks down the landmark findings, and explains why this trial is now considered practice changing.

During the 2026 NCCN Annual Conference, Sandy Srinivas, MD, emphasized that HRR mutation testing in advanced prostate cancer is underutilized.

Learn how age, TP53 risk, and lifestyle shape choosing fixed-duration vs continuous CLL therapy, with shared decision tips from Dr Lamanna.

Historically, treating patients with urothelial carcinoma who were considered cisplatin-ineligible due to insufficient kidney function was a signifcant unmet need; however with enfortumab vedotin entering the frontline space, these patients have another option open to them.